Covered recipient · General Payments record
ALBERTO BESSUDO
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$3,923.74
152 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,875.33 | 149 |
| Education | $48.41 | 3 |
By paying entity
PY2025 · entire year · sorted by reported total
Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ALBERTO BESSUDO
NPI 1003888074 · CMS profile ID 226877
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
ENCINITAS, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1003888074?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ALBERTO BESSUDO, NPI 1003888074, CMS profile ID 226877. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003888074?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ALBERTO BESSUDO, NPI 1003888074, CMS profile ID 226877. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003888074?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ALBERTO BESSUDO, NPI 1003888074, CMS profile ID 226877, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1003888074?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
152 matching records · $3,923.74 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 152.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $19.30 | 05/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184933983 | CMS |
| Novartis Pharmaceuticals Corporation | $28.22 | 05/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200118322 | CMS |
| Celgene Corporation | $32.70 | 05/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184933987 | CMS |
| E.R. Squibb & Sons, L.L.C. | $23.33 | 05/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184933989 | CMS |
| PFIZER INC. | $18.73 | 05/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229132585 | CMS |
| ACCORD HEALTHCARE, INC. | $22.40 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248752504 | CMS |
| ARRAY BIOPHARMA INC | $25.93 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229213012 | CMS |
| Gilead Sciences, Inc. | $14.62 | 05/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234574076 | CMS |
| E.R. Squibb & Sons, L.L.C. | $27.93 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184933977 | CMS |
| Novartis Pharmaceuticals Corporation | $17.42 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200118320 | CMS |
| Eisai Inc. | $26.45 | 05/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244457399 | CMS |
| PFIZER INC. | $14.93 | 05/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229213004 | CMS |
| ABBVIE INC. | $20.10 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201510078 | CMS |
| Exelixis Inc. | $23.07 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218790245 | CMS |
| PFIZER INC. | $22.27 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229238228 | CMS |
| PFIZER INC. | $20.07 | 04/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228931931 | CMS |
| Coherus Oncology, Inc. | $22.56 | 04/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235235604 | CMS |
| Eisai Inc. | $24.44 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1244457397 | CMS |
| Gilead Sciences, Inc. | $26.14 | 04/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234464913 | CMS |
| Exelixis Inc. | $35.39 | 04/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218790247 | CMS |
| Syndax Pharmaceuticals, Inc. | $27.47 | 04/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238989946 | CMS |
| Novartis Pharmaceuticals Corporation | $27.99 | 04/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200118310 | CMS |
| Exelixis Inc. | $27.45 | 04/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218790249 | CMS |
| Alexion Pharmaceuticals, Inc. | $29.26 | 04/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202969592 | CMS |
| GENZYME CORPORATION | $121.01 | 04/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233275205 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.09 | 03/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184933975 | CMS |
| BeOne Medicines USA, Inc. | $23.83 | 03/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202901246 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.55 | 03/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184933941 | CMS |
| Exelixis Inc. | $17.89 | 03/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218790251 | CMS |
| ABBVIE INC. | $24.46 | 03/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201510076 | CMS |
| Cumberland Pharmaceuticals, Inc. | $13.50 | 03/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1242137507 | CMS |
| Daiichi Sankyo Inc. | $20.72 | 03/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197046751 | CMS |
| Novartis Pharmaceuticals Corporation | $18.50 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200118308 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.08 | 03/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184933943 | CMS |
| Celgene Corporation | $21.10 | 03/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184933951 | CMS |
| SOBI, INC | $25.10 | 03/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240224308 | CMS |
| Merck Sharp & Dohme LLC | $15.72 | 03/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238149916 | CMS |
| Daiichi Sankyo Inc. | $20.17 | 03/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197052409 | CMS |
| Sumitomo Pharma America, Inc. | $24.06 | 03/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1176603184 | CMS |
| SOBI, INC | $29.53 | 02/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240224304 | CMS |
| E.R. Squibb & Sons, L.L.C. | $28.45 | 02/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184933933 | CMS |
| Merck Sharp & Dohme LLC | $34.64 | 02/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238276847 | CMS |
| PFIZER INC. | $7.10 | 02/15/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228870557 | CMS |
| E.R. Squibb & Sons, L.L.C. | $8.34 | 02/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184933935 | CMS |
| Gilead Sciences, Inc. | $1.95 | 02/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234609505 | CMS |
| PFIZER INC. | $4.38 | 02/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228877797 | CMS |
| Alexion Pharmaceuticals, Inc. | $30.95 | 02/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202953432 | CMS |
| Exelixis Inc. | $36.02 | 01/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1218790243 | CMS |
| Alexion Pharmaceuticals, Inc. | $33.92 | 01/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1202948338 | CMS |
| Aveo Pharmaceuticals, Inc. | $20.00 | 01/08/2025 | Education | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1199898644 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $96,620.75 | 31 |
| PY2024 | Recipient | $746.00 | 1 |
| PY2024 | Principal investigator | $131,888.56 | 35 |
| PY2023 | Principal investigator | $417,974.29 | 45 |
| PY2022 | Principal investigator | $85,479.23 | 11 |
| PY2021 | Principal investigator | $524,383.39 | 34 |
| PY2020 | Principal investigator | $1,145,676.90 | 254 |
| PY2019 | Principal investigator | $1,538,125.60 | 302 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
31 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $650.00 | 12/22/2025 | Non-covered Recipient Entity CA Cancer Associates Res Excel | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228713222 |
| Principal investigator 1 | PFIZER INC. | $1,300.00 | 11/24/2025 | Non-covered Recipient Entity CA Cancer Associates Res Excel | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228713404 |
| Principal investigator 1 | PFIZER INC. | $7,152.00 | 11/14/2025 | Non-covered Recipient Entity California Cancer Associates for Research and Excellence Inc | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228818128 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 10/27/2025 | Non-covered Recipient Entity CA Cancer Associates Res Excel | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228713402 |
| Principal investigator 1 | PFIZER INC. | $2,384.00 | 10/09/2025 | Non-covered Recipient Entity California Cancer Associates for Research and Excellence Inc | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228824844 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $345.00 | 09/26/2025 | Non-covered Recipient Entity ADVARRA | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192105034 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $250.00 | 09/18/2025 | Non-covered Recipient Entity CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC | AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB | No dispute reported | 06/30/2026 | 1192103525 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,405.75 | 09/18/2025 | Non-covered Recipient Entity CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC | AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB | No dispute reported | 06/30/2026 | 1192103532 |
| Principal investigator 1 | PFIZER INC. | $38,167.50 | 09/16/2025 | Non-covered Recipient Entity California Cancer Associates for Research and Excellence Inc | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228835972 |
| Principal investigator 1 | PFIZER INC. | $2,384.00 | 09/09/2025 | Non-covered Recipient Entity California Cancer Associates for Research and Excellence Inc | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228836036 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,800.00 | 08/27/2025 | Non-covered Recipient Entity INTERSPOND LLC | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192103490 |
| Principal investigator 1 | PFIZER INC. | $2,384.00 | 08/06/2025 | Non-covered Recipient Entity California Cancer Associates for Research and Excellence Inc | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228843601 |
| Principal investigator 1 | PFIZER INC. | $1,300.00 | 07/29/2025 | Non-covered Recipient Entity CA Cancer Associates Res Excel | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228713220 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $750.00 | 07/22/2025 | Non-covered Recipient Entity INTERSPOND LLC | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | No dispute reported | 06/30/2026 | 1192103495 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,694.00 | 06/20/2025 | Non-covered Recipient Entity California Cancer Assocs.for Research and Excellence | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246662824 |
| Principal investigator 1 | PFIZER INC. | $2,384.00 | 06/06/2025 | Non-covered Recipient Entity California Cancer Associates for Research and Excellence Inc | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228852098 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,405.75 | 06/05/2025 | Non-covered Recipient Entity CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC | AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB | No dispute reported | 06/30/2026 | 1192103519 |
| Principal investigator 1 | PFIZER INC. | $2,384.00 | 05/14/2025 | Non-covered Recipient Entity California Cancer Associates for Research and Excellence Inc | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228857674 |
| Principal investigator 1 | PFIZER INC. | $2,384.00 | 05/01/2025 | Non-covered Recipient Entity California Cancer Associates for Research and Excellence Inc | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228857721 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $532.80 | 04/16/2025 | Non-covered Recipient Entity CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE | Ph III GDC 199 GA101 vs GChl in CLL with comorbidities | No dispute reported | 06/30/2026 | 1211582487 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $624.96 | 04/16/2025 | Non-covered Recipient Entity CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE | Ph III GDC 199 GA101 vs GChl in CLL with comorbidities | No dispute reported | 06/30/2026 | 1211582491 |
| Principal investigator 1 | Eli Lilly and Company | $76.95 | 04/08/2025 | Non-covered Recipient Entity CANCER CAR ASSOCIATES OF FRESNO MEDICAL GROUP | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) | No dispute reported | 06/30/2026 | 1187876155 |
| Principal investigator 1 | PFIZER INC. | $1,625.00 | 03/31/2025 | Non-covered Recipient Entity CA Cancer Associates Res Excel | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228840946 |
| Principal investigator 1 | PFIZER INC. | $2,384.00 | 03/14/2025 | Non-covered Recipient Entity California Cancer Associates for Research and Excellence Inc | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228862508 |
| Principal investigator 1 | PFIZER INC. | $2,384.00 | 02/14/2025 | Non-covered Recipient Entity California Cancer Associates for Research and Excellence Inc | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228835977 |
| Principal investigator 1 | Eli Lilly and Company | $8,393.26 | 01/22/2025 | Non-covered Recipient Entity CANCER CAR ASSOCIATES OF FRESNO MEDICAL GROUP | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) | No dispute reported | 06/30/2026 | 1187875425 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,405.75 | 01/16/2025 | Non-covered Recipient Entity CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC | AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB | No dispute reported | 06/30/2026 | 1192103506 |
| Principal investigator 1 | PFIZER INC. | $2,384.00 | 01/15/2025 | Non-covered Recipient Entity California Cancer Associates for Research and Excellence Inc | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228863630 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $854.83 | 01/09/2025 | Non-covered Recipient Entity CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC | AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB | No dispute reported | 06/30/2026 | 1192103501 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $550.92 | 01/09/2025 | Non-covered Recipient Entity CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC | AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB | No dispute reported | 06/30/2026 | 1192103512 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,230.28 | 01/09/2025 | Non-covered Recipient Entity CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 1184147345 |